News Focus
News Focus
Post# of 257426
Next 10
Followers 843
Posts 122876
Boards Moderated 9
Alias Born 09/05/2002

Re: DewDiligence post# 244811

Wednesday, 01/25/2023 7:26:52 PM

Wednesday, January 25, 2023 7:26:52 PM

Post# of 257426
MGTA—(-24%/AH)—pauses_phase-1/2_trial_in AML/MDS after_patient_death deemed “possibly drug-related”:

https://finance.yahoo.com/news/magenta-therapeutics-voluntarily-pauses-mgta-210500940.html

Magenta Therapeutics today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) experienced a Grade 5 Serious Adverse Event (SAE) (respiratory failure and cardiac arrest resulting in death) deemed to be possibly related to MGTA-117.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today